Trial · NCT00826449
Adverse events100
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 100
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Dasatinib + Erlotinib | 5 | 47 | 7 |
| other | Acidosis | Metabolism and nutrition disorders | Dasatinib + Erlotinib | 1 | 47 | 2 |
| other | Activated partial thromboplastin time prolonged | Blood and lymphatic system disorders | Dasatinib + Erlotinib | 3 | 47 | 3 |
| other | Alanine aminotransferase increased | Metabolism and nutrition disorders | Dasatinib + Erlotinib | 9 | 47 | 10 |
| other | Alkaline phosphatase increased | Metabolism and nutrition disorders | Dasatinib + Erlotinib | 11 | 47 | 17 |
| other | Allergic rhinitis | Immune system disorders | Dasatinib + Erlotinib | 4 | 47 | 4 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Dasatinib + Erlotinib | 2 | 47 | 2 |
| other | Anorexia | Gastrointestinal disorders | Dasatinib + Erlotinib | 18 | 47 | 20 |
| other | Anxiety | Nervous system disorders | Dasatinib + Erlotinib | 7 | 47 | 7 |
| other | Arrhythmia supraventricular | Cardiac disorders | Dasatinib + Erlotinib | 1 | 47 | 1 |
| other | Aspartate aminotransferase increased | Metabolism and nutrition disorders | Dasatinib + Erlotinib | 15 | 47 | 23 |
| other | Aspiration | Respiratory, thoracic and mediastinal disorders | Dasatinib + Erlotinib | 1 | 47 | 1 |
| other | Auditory/Ear | Ear and labyrinth disorders | Dasatinib + Erlotinib | 2 | 47 | 2 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Dasatinib + Erlotinib | 4 | 47 | 4 |
| other | Bilirubin increased | Metabolism and nutrition disorders | Dasatinib + Erlotinib | 4 | 47 | 8 |
| other | Bladder hemorrhage | Renal and urinary disorders | Dasatinib + Erlotinib | 1 | 47 | 1 |
| other | Blood glucose increased | Metabolism and nutrition disorders | Dasatinib + Erlotinib | 24 | 47 | 54 |
| other | Blood uric acid increased | Metabolism and nutrition disorders | Dasatinib + Erlotinib | 4 | 47 | 4 |
| other | Blood/Bone Marrow | Blood and lymphatic system disorders | Dasatinib + Erlotinib | 1 | 47 | 3 |
| other | Bone pain | Musculoskeletal and connective tissue disorders | Dasatinib + Erlotinib | 1 | 47 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00826449/events